3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
4
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
2
Tumor-Agnostic
1
Conditions
Neoplasms
1
Anemia, Iron-Deficiency
1
Anemia
1
Interventions
Epoetin Alfa
38
Darbepoetin alfa
30
epoetin beta
10
Rivaroxaban
9
olaparib
5
eltrombopag
5
apixaban
5
Heparin, Low-Molecular-Weight
5
pegylated granulocyte colony-stimulating factor
4
pegfilgrastim
4
emicizumab
4
Gemcitabine
4
Filgrastim
4
Dalteparin
4
Cyclophosphamide
4
AP 1903 reagent
4
romiplostim
3
peginesatide
3
luspatercept
3
hetrombopag
3
hematide
3
Vancomycin
3
ON 01910
3
Enoxaparin
3
Azacitidine
3
ACE-011
3
venetoclax
2
telapristone acetate
2
roxadustat
2
iron isomaltoside 1000
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
iron isomaltoside 1000
×
Classical hematology
×
Clear all
NCT04318405
2023-07-19
Real-CHOICE
Pierre Fabre Pharma AG
Completed
327 enrolled
NCT01280240
2013-06-04
PK-CIA-06
Pharmacosmos A/S
Phase 1
Completed
11 enrolled